image
Healthcare - Biotechnology - NASDAQ - US
$ 6.97
-3.82 %
$ 42.6 M
Market Cap
-0.35
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one ALGS stock under the worst case scenario is HIDDEN Compared to the current market price of 6.97 USD, Aligos Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one ALGS stock under the base case scenario is HIDDEN Compared to the current market price of 6.97 USD, Aligos Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one ALGS stock under the best case scenario is HIDDEN Compared to the current market price of 6.97 USD, Aligos Therapeutics, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart ALGS

image
$50.0$50.0$45.0$45.0$40.0$40.0$35.0$35.0$30.0$30.0$25.0$25.0$20.0$20.0$15.0$15.0$10.0$10.0$5.0$5.0$0.0$0.015 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '25
FINANCIALS
3.94 M REVENUE
-74.60%
-89.2 M OPERATING INCOME
-1.17%
-131 M NET INCOME
-49.65%
-80.7 M OPERATING CASH FLOW
-2.21%
-18.3 M INVESTING CASH FLOW
-40.64%
355 K FINANCING CASH FLOW
-99.60%
311 K REVENUE
-50.56%
-19.2 M OPERATING INCOME
6.42%
43.1 M NET INCOME
152.45%
-20.9 M OPERATING CASH FLOW
-13.62%
-44.1 M INVESTING CASH FLOW
-220.64%
102 M FINANCING CASH FLOW
104788.66%
Balance Sheet Aligos Therapeutics, Inc.
image
Current Assets 62.1 M
Cash & Short-Term Investments 56.9 M
Receivables 0
Other Current Assets 5.2 M
Non-Current Assets 7.95 M
Long-Term Investments 0
PP&E 7.33 M
Other Non-Current Assets 627 K
81.23 %7.42 %10.45 %Total Assets$70.1m
Current Liabilities 21.7 M
Accounts Payable 2.57 M
Short-Term Debt 3.46 M
Other Current Liabilities 15.7 M
Non-Current Liabilities 77.3 M
Long-Term Debt 4.92 M
Other Non-Current Liabilities 72.4 M
3.49 %15.86 %4.96 %73.09 %Total Liabilities$99.1m
EFFICIENCY
Earnings Waterfall Aligos Therapeutics, Inc.
image
Revenue 3.94 M
Cost Of Revenue 0
Gross Profit 1.32 M
Operating Expenses 93.1 M
Operating Income -89.2 M
Other Expenses 42.1 M
Net Income -131 M
20m20m00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)(140m)(140m)4m01m(93m)(89m)(42m)(131m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
33.54% GROSS MARGIN
33.54%
-2259.92% OPERATING MARGIN
-2259.92%
-3326.01% NET MARGIN
-3326.01%
452.87% ROE
452.87%
-187.19% ROA
-187.19%
-172.50% ROIC
-172.50%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Aligos Therapeutics, Inc.
image
00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)20192019202020202021202120222022202320232024202420252025
Net Income -131 M
Depreciation & Amortization 2.62 M
Capital Expenditures -130 K
Stock-Based Compensation 8.45 M
Change in Working Capital -4.96 M
Others 39.3 M
Free Cash Flow -80.9 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Aligos Therapeutics, Inc.
image
ALGS has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 6
6. Ownership
Insider Ownership Aligos Therapeutics, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Aligos Therapeutics to Present at the Jefferies Global Healthcare Conference SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that members of management will present at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025 at 2:00pm ET. globenewswire.com - 3 weeks ago
Aligos Therapeutics Appoints Laura Kavanaugh as Vice President, Head of Legal SOUTH SAN FRANCISCO, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Laura Kavanaugh, JD as Vice President, Head of Legal, effective immediately. globenewswire.com - 1 month ago
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., May 16, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company's Board of Directors granted a non-qualified stock option to purchase an aggregate of 26,000 shares of the Company's stock (the “Inducement Grant”) to a newly hired employee on May 13, 2025 (the “Grant Date”), in connection with the commencement of employment. globenewswire.com - 1 month ago
Aligos Therapeutics Presents Positive Data at the EASL Congress 2025 SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced positive data from eight presentations at the European Association for the Study of the Liver (EASL) Congress 2025, being held May 7 – 10, 2025 in Amsterdam, Netherlands. globenewswire.com - 1 month ago
Aligos Therapeutics, Inc. (ALGS) Reports Q1 Loss, Misses Revenue Estimates Aligos Therapeutics, Inc. (ALGS) came out with a quarterly loss of $2.11 per share versus the Zacks Consensus Estimate of a loss of $2.80. This compares to loss of $5.50 per share a year ago. zacks.com - 1 month ago
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2025 Financial Results SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today reported recent business progress and financial results for the first quarter 2025. globenewswire.com - 1 month ago
Aligos Therapeutics to Announce 1st Quarter 2025 Financial Results on May 6, 2025 SOUTH SAN FRANCISCO, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that it will report the Company's first quarter 2025 financial results on Tuesday, May 6, 2025, before the open of the U.S. financial markets. globenewswire.com - 1 month ago
Aligos Therapeutics Announces Eight Abstracts Accepted for Presentation at the EASL Congress 2025 SOUTH SAN FRANCISCO, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced eight abstracts have been accepted for poster presentations at the European Association for the Study of the Liver (EASL) Congress 2025, being held May 7 – 10, 2025 in Amsterdam, Netherlands. The abstracts released today can be found on the EASL website at https://www.easlcongress.eu/. globenewswire.com - 1 month ago
LIVMARLI Now Approved in Japan for ALGS and PFIC FOSTER CITY, Calif.--(BUSINESS WIRE)-- #alagillesyndrome--LIVMARLI Now Approved in Japan for ALGS and PFIC. businesswire.com - 2 months ago
Aligos Therapeutics Presents Positive Data at APASL 2025 SOUTH SAN FRANCISCO, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced positive data from three oral presentations at the 34th Annual Meeting of the Asian Pacific Association for the Study of the Liver (APASL) 2025, being held March 26 - 30, 2025 in Beijing, China. globenewswire.com - 2 months ago
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., March 14, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company's Board of Directors granted a non-qualified stock option to purchase an aggregate of 4,000 shares of the Company's stock (the “Inducement Grant”) to a newly hired employee on March 11, 2025 (the “Grant Date”), in connection with the commencement of employment. globenewswire.com - 3 months ago
Aligos Therapeutics, Inc. (ALGS) Reports Q4 Loss, Lags Revenue Estimates Aligos Therapeutics, Inc. (ALGS) came out with a quarterly loss of $3.41 per share versus the Zacks Consensus Estimate of a loss of $1.91. This compares to loss of $5.50 per share a year ago. zacks.com - 3 months ago
8. Profile Summary

Aligos Therapeutics, Inc. ALGS

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 42.6 M
Dividend Yield 0.00%
Description Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-ß agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, it develops siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. It has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH. The company was incorporated in 2018 and is headquartered in South San Francisco, California.
Contact One Corporate Drive, South San Francisco, CA, 94080 https://www.aligos.com
IPO Date Oct. 16, 2020
Employees 70
Officers Ms. Lesley Ann Calhoun CPA Executive Vice President, Chief Financial Officer & Chief Operating Officer Dr. Julian A. Symons DPHIL Executive Vice President & Chief Scientific Officer Dr. Tse-I Lin Ph.D. Senior Vice President of Early Compound Development & Belgian Site Head Dr. Sushmita M. Chanda DABT, Ph.D. Executive Vice President & Chief Development Officer Dr. Lawrence M. Blatt MBA, Ph.D. Chief Executive Officer, President & Chairman of the Board Ms. Kristina Engeseth M.B.A. Senior Vice President and Head of People & Culture Dr. David B. Smith Ph.D. Executive Vice President & Head of Chemical Operations Dr. Hardean E. Achneck M.D. Executive Vice President & Chief Medical Officer